Genmab A/S

About Genmab A/S

Genmab A/S is a leading biotechnology company based in the UK, dedicated to the development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has established itself as a pioneer in the field of immunotherapy, focusing on creating innovative treatments that harness the body’s immune system to fight cancer.

With a robust pipeline of product candidates, Genmab is committed to advancing its proprietary technologies and collaborating with other industry leaders to bring new therapies to market. The company’s flagship product, Daratumumab, has transformed the treatment landscape for multiple myeloma and showcases Genmab’s expertise in monoclonal antibody development.

Genmab’s vision is to improve the lives of patients by delivering best-in-class therapies that address unmet medical needs. The company invests heavily in research and development, employing a talented team of scientists and professionals who are passionate about innovation and excellence.

In addition to its focus on oncology, Genmab is exploring opportunities in other therapeutic areas, including autoimmune diseases. The company’s commitment to scientific advancement is reflected in its strong intellectual property portfolio and numerous partnerships with leading pharmaceutical companies.

Genmab A/S operates with a strong emphasis on corporate responsibility, ensuring that its operations are sustainable and ethically sound. The company is also dedicated to fostering a diverse and inclusive workplace, recognizing that a variety of perspectives drives creativity and innovation.

As Genmab continues to grow, it remains focused on its mission to develop transformative therapies that make a meaningful difference in the lives of patients worldwide.